NCT04615273: A trial that was reported late by Ascendis Pharma Endocrinology Division A/S
This trial has reported, although it was 48 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04615273 |
|---|---|
| Title | foresiGHt: A Multicenter, Randomized, Parallel-arm, Placebo-controlled (Double- Blind) and Active-controlled (Open-label) Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 3, 2020 |
| Completion date | Nov. 2, 2023 |
| Required reporting date | Nov. 1, 2024, midnight |
| Actual reporting date | Dec. 20, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 48 |